January 14, 2019

FDA’s approval of Cabometyx was based on results from the phase III pivotal trial of Cabometyx for patients with advanced HCC who received prior sorafenib

ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S.1 “This new indication for CABOMETYX is […]

Read more